Your browser doesn't support javascript.
loading
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Powles, Ryan L; Redmond, David; Sotiriou, Christos; Loi, Sherene; Fumagalli, Debora; Nuciforo, Paolo; Harbeck, Nadia; de Azambuja, Evandro; Sarp, Severine; Di Cosimo, Serena; Huober, Jens; Baselga, Jose; Piccart-Gebhart, Martine; Elemento, Olivier; Pusztai, Lajos; Hatzis, Christos.
Afiliación
  • Powles RL; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
  • Redmond D; Computational Biology and Bioinformatics Program, Yale University, New Haven, Connecticut.
  • Sotiriou C; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York.
  • Loi S; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Fumagalli D; Division of Cancer Medicine and Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia.
  • Nuciforo P; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Harbeck N; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • de Azambuja E; Department of Obstetrics and Gynecology, University of Munich, Munich, Germany.
  • Sarp S; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Di Cosimo S; Novartis AG, Basel, Switzerland.
  • Huober J; Department of Oncology, Istituto Nazionale Tumori, Milan, Italy.
  • Baselga J; Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany.
  • Piccart-Gebhart M; Breast Medical Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Elemento O; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Pusztai L; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York.
  • Hatzis C; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medical College, New York, New York.
JAMA Oncol ; 4(11): e181564, 2018 11 01.
Article en En | MEDLINE | ID: mdl-29902299
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Antígenos de Linfocitos T / Receptor ErbB-2 / Trastuzumab / Lapatinib Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: JAMA Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Antígenos de Linfocitos T / Receptor ErbB-2 / Trastuzumab / Lapatinib Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: JAMA Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos